VistaGen Therapeutics (VTGN) Price/OCF Ratio: History & Chart

VistaGen Therapeutics, Inc.(VTGN)

Biotechnology · South San Francisco, CA

$0.25-0.01 (-4.79%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

South San Francisco, CA

41 employees

www.vistagen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shawn K. Singh

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
VistaGen Therapeutics, Inc. (VTGN)	$11.12M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$11.01M	N/A	N/A	N/A	N/A
CytoMed Therapeutics Limited (GDTC)vs ›	$11.00M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.29M	N/A	5.31	5.31	5.31
Cerenome, Inc. (CNSY)vs ›	$10.94M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.39M	N/A	6.96	6.96	6.96
Caring Brands, Inc. (CABR)vs ›	$11.46M	N/A	N/A	N/A	N/A
Phio Pharmaceuticals Corp. (PHIO)vs ›	$11.55M	N/A	N/A	N/A	N/A
Pluri Inc. (PLUR)vs ›	$10.68M	N/A	N/A	N/A	N/A
IRIDEX Corporation (IRIX)vs ›	$11.77M	N/A	9.81	9.81	9.81

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

VistaGen Therapeutics, Inc. (VTGN)

$11.12M

N/A

BioVie Inc. (BIVI)vs ›

$11.01M

N/A

CytoMed Therapeutics Limited (GDTC)vs ›

$11.00M

N/A

Lisata Therapeutics, Inc. (LSTA)vs ›

$11.29M

N/A

5.31

Cerenome, Inc. (CNSY)vs ›

$10.94M

N/A

Kiora Pharmaceuticals, Inc. (KPRX)vs ›

$11.39M

N/A

6.96

Caring Brands, Inc. (CABR)vs ›

$11.46M

N/A

Phio Pharmaceuticals Corp. (PHIO)vs ›

$11.55M

N/A

Pluri Inc. (PLUR)vs ›

$10.68M

N/A

IRIDEX Corporation (IRIX)vs ›

$11.77M

N/A

9.81

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

VTGN Price/OCF Ratio Metrics

VTGN Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics